Literature DB >> 1978476

Treatment programme and long-term outcome in chronic schizophrenia.

J M Kane1.   

Abstract

Antipsychotic drug treatment is usually started during an acute episode or exacerbation of a pre-existing psychosis. Although the medication has marked therapeutic benefit for most patients, ther is considerable heterogeneity in drug response. A variety of factors may influence this response, but at present we have no well-established predictors which would help targeting specific pharmacological treatments. The continuation of antipsychotic drug treatment to control persistent symptoms and to prevent further exacerbations or relapse has become a mainstay in the long-term treatment of schizophrenia. There are various considerations which come into play in deciding which patients should receive such treatment, at what dose, and for how long. Research in recent years has attempted to identify strategies to minimize the risks associated with long-term treatment (particularly tardive dyskinesia). In addition, other factors influencing long-term outcome have been better studied in combination with controlled drug treatment.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1978476     DOI: 10.1111/j.1600-0447.1990.tb05309.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand Suppl        ISSN: 0065-1591


  17 in total

Review 1.  Zotepine versus other atypical antipsychotics for schizophrenia.

Authors:  Selvizhi Subramanian; Christine Rummel-Kluge; Heike Hunger; Franziska Schmid; Sandra Schwarz; Werner Kissling; Stefan Leucht; Katja Komossa
Journal:  Cochrane Database Syst Rev       Date:  2010-10-06

Review 2.  Sertindole versus other atypical antipsychotics for schizophrenia.

Authors:  Katja Komossa; Christine Rummel-Kluge; Heike Hunger; Sandra Schwarz; Franziska Schmidt; Ruth Lewis; Werner Kissling; Stefan Leucht
Journal:  Cochrane Database Syst Rev       Date:  2009-04-15

Review 3.  Clozapine dose for schizophrenia.

Authors:  Selvizhi Subramanian; Birgit A Völlm; Nick Huband
Journal:  Cochrane Database Syst Rev       Date:  2017-06-14

Review 4.  Amisulpride: a review of its use in the management of schizophrenia.

Authors:  M P Curran; C M Perry
Journal:  Drugs       Date:  2001       Impact factor: 9.546

Review 5.  WITHDRAWN: Risperidone versus other atypical antipsychotic medication for schizophrenia.

Authors:  Simon Gilbody; Anne-Marie Bagnall; Lorna Duggan; Arja Tuunainen
Journal:  Cochrane Database Syst Rev       Date:  2016-09-20

Review 6.  Olanzapine versus other atypical antipsychotics for schizophrenia.

Authors:  Katja Komossa; Christine Rummel-Kluge; Heike Hunger; Franziska Schmid; Sandra Schwarz; Lorna Duggan; Werner Kissling; Stefan Leucht
Journal:  Cochrane Database Syst Rev       Date:  2010-03-17

7.  Tolerability of remoxipride in the long term treatment of schizophrenia. An overview.

Authors:  A C Holm; I Edsman; T Lundberg; B Odlind
Journal:  Drug Saf       Date:  1993-06       Impact factor: 5.606

Review 8.  Quetiapine versus other atypical antipsychotics for schizophrenia.

Authors:  Katja Komossa; Christine Rummel-Kluge; Franziska Schmid; Heike Hunger; Sandra Schwarz; Manit Srisurapanont; Werner Kissling; Stefan Leucht
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20

Review 9.  Amisulpride versus other atypical antipsychotics for schizophrenia.

Authors:  Katja Komossa; Christine Rummel-Kluge; Heike Hunger; Franziska Schmid; Sandra Schwarz; Joaquim I Silveira da Mota Neto; Werner Kissling; Stefan Leucht
Journal:  Cochrane Database Syst Rev       Date:  2010-01-20

Review 10.  Aripiprazole versus other atypical antipsychotics for schizophrenia.

Authors:  Katja Komossa; Christine Rummel-Kluge; Franziska Schmid; Heike Hunger; Sandra Schwarz; Hany George G El-Sayeh; Werner Kissling; Stefan Leucht
Journal:  Cochrane Database Syst Rev       Date:  2009-10-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.